Search company, investor...
FloraSeq company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Grant | Alive

Total Raised


Last Raised

$50K | 7 yrs ago

About FloraSeq

FloraSeq is developing products that promote gastrointestinal health and relieve ailments, as well as complementary clinical laboratory services for diagnosing infectious diseases and gastrointestinal problems.

FloraSeq Headquarters Location

Waukesha, Wisconsin,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing FloraSeq

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

FloraSeq is included in 1 Expert Collection, including Omics.



275 items

Latest FloraSeq News

FloraSeq LLC’s ’poop pill’ not for the squeamish

Mar 12, 2016

(0) Comments Michael McLoone To make the pills, FloraSeq scientists process donated stool samples to isolate the bacteria. For raw materials, the start-up screens friends and family. The main ingredient in a pill being developed by FloraSeq LLC will undoubtedly put patients off. But if FloraSeq's founders are correct, and the pill cures a stubborn and prevalent hospital-acquired infection, patients are likely to get past the ingredient — human feces. "There's a popular misconception that all stool is teaming with harmful bacteria such as E. coli or salmonella, which can cause large outbreaks of illness, but that is seldom true," said Steve Visuri, co-founder, president and chief executive officer of the Waukesha start-up. "While we don't recommend people routinely ingest stool, carefully screened stool from healthy individuals is actually filled with an exceptional amount of beneficial bacteria that can be used to cure patients with intestinal infections. " The bottom line: FloraSeq is developing a pill to be ingested orally that is teaming with good bacteria from other people's stool samples. The human gut is home to as many as 100 trillion microorganisms, representing about 400 known bacterial species, Visuri said. In the past few years, scientist have become increasingly interested in those bacteria, whose genes are collectively referred to as the human microbiome. "One of the hottest areas of research right now is microbiomes," said Lisa Johnson, chief executive officer of BioForward , the trade organization for Wisconsin's bioscience industry. Researchers have been finding connections between bacteria in the gut and diabetes , lupus and other autoimmune diseases and other conditions , Johnson said. The problem FloraSeq is trying to fix often occurs after long-term use of antibiotics wipes out the good bacteria and allows the bad bacteria to grow out of control. Among the worst culprits is the C. difficile bacterium, which can cause horrible diarrhea, abdominal pain and other symptoms, said Dan Stein, director of the Irritable Bowel Disease Program at Froedtert Hospital. Antibiotics are the standard treatment for C. difficile infections, but they don't work in 15% to 20% of patients, Stein said. Fecal transplants — where a healthy donor's stool is transferred into the patient's gastrointestinal tract through colonoscopy, endoscopy or other invasive procedures — have grown in popularity during the past five years as the next option and have a 90% to 95% cure rate, he said. FloraSeq's pill would theoretically have the same effectiveness as a fecal transplant, but with a more palatable delivery method. "The reality is that about 200,000 patients a year fail antibiotics and live absolutely miserable lives for months or years, and 30,000 of them succumb to their illness," Visuri said. "These are the desperate patients we're focused on helping with our poop pills. " The pill, which has no smell and no taste, may take as many as four years to get to market, Visuri said. But there are many reasons its path to commercialization looks promising. There is a large potential market for the pill, said Todd Sobotka, investment manager at BrightStar Wisconsin. BrightStar recently invested $50,000 in FloraSeq to help the start-up prove the feasibility of its idea; it was the first time that the foundation was the sole investor in a deal, Sobotka said. FloraSeq should be on a fast track for regulatory approval because the underlying therapy has been proven with fecal transplants, he said. And Visuri and his partner, Karen Harrington, are known to several BrightStar officials. Visuri and Harrington worked at Prodesse Inc. and companies that acquired it. Tom Shannon, BrightStar's top executive, led Prodesse to a sale in 2009 to Gen-Probe Inc. While at Prodesse, Visuri and Harrington were part of the team that created a test for diagnosing the C. difficile bacterium. "It's a pretty compelling opportunity — the kind that doesn't come around often," Sobotka said. FloraSeq, which formed in September 2014, is working to develop a patent portfolio around its methods and manufacture of materials and donor selection, Visuri said. For raw materials, the start-up relies on friends and family — they're screened in a similar way to blood donors — to provide donations. To make the pills, FloraSeq scientists process the donated stool samples to isolate the bacteria — it currently has the dose down to eight pills, Visuri said. "That's probably our biggest technical challenge; to maintain the viability of the bacteria and concentrate them down," he said. Study of the human microbiome — all of the microorganisms that live on our skin and in our bodies — is a hot topic in science and is increasingly translating into commercial products. One competitor to FloraSeq's pill is Seres Therapeutics in Boston. Seres is well-funded and a year or two ahead of FloraSeq, so the Wisconsin start-up "has some catching up to do," Visuri said. But Seres is intentionally killing off many of the bacteria, while FloraSeq is taking the opposite approach, he said. Scientists don't really have a good sense of what a healthy gut looks like, but they know that the more diverse the bacteria, the better, Visuri said. "What we're aiming to do is to re-establish a wide variety of the gut bacteria," he said. PODCAST: Behind the Headlines To hear reporter Kathleen Gallagher talk about this story, listen to this week's Behind the Headlines podcast, available Sunday at, or subscribe in the iTunes store or through Stitcher Radio. TIPS FOR A HEALTHY GUT The human gut contains 10 times more bacteria than all the human cells in the entire body, said Steve Visuri, FloraSeq LLC's founder, president and chief executive officer. "In fact, you could say that we're more bacterial than we are human," Visuri said. "So we should not only focus on feeding ourselves, but on feeding our bacteria. " Here are Visuri's tips for maintaining a healthy gut: ■Avoid antibiotics unless they are medically necessary. ■Limit refined sugars and avoid unnatural sweeteners. ■Eat real food; limit processed food. ■Eat plenty of fermentable fibers (starches like sweet potato, yam, bananas, legumes and oats). ■Eat fermented foods (i.e. kefir, yogurt, sauerkraut, kim chi). ■Get enough sleep and reduce stress. © 2016 , Journal Sentinel Inc. All rights reserved.

  • Where is FloraSeq's headquarters?

    FloraSeq's headquarters is located at Waukesha.

  • What is FloraSeq's latest funding round?

    FloraSeq's latest funding round is Grant.

  • How much did FloraSeq raise?

    FloraSeq raised a total of $50K.

  • Who are the investors of FloraSeq?

    Investors of FloraSeq include BrightStar Wisconsin.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.